What is HC Wainwright’s Forecast for CRVS FY2028 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Research analysts at HC Wainwright decreased their FY2028 earnings per share estimates for Corvus Pharmaceuticals in a note issued to investors on Wednesday, March 26th. HC Wainwright analyst S. Lee now expects that the company will earn $0.11 per share for the year, down from their previous estimate of $0.14. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2029 earnings at $0.44 EPS.

Separately, Oppenheimer reissued an “outperform” rating and issued a $15.00 target price (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research note on Wednesday. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $15.67.

Corvus Pharmaceuticals Price Performance

CRVS stock opened at $3.37 on Thursday. The company’s 50 day simple moving average is $4.64 and its 200-day simple moving average is $6.06. The firm has a market capitalization of $216.55 million, a PE ratio of -3.62 and a beta of 0.91. Corvus Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $10.00.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.06).

Hedge Funds Weigh In On Corvus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in CRVS. Geode Capital Management LLC increased its position in shares of Corvus Pharmaceuticals by 22.4% in the third quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock worth $2,974,000 after acquiring an additional 102,869 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter valued at approximately $265,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Corvus Pharmaceuticals by 64.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock worth $724,000 after buying an additional 53,809 shares during the last quarter. State Street Corp boosted its stake in Corvus Pharmaceuticals by 48.2% in the third quarter. State Street Corp now owns 178,246 shares of the company’s stock valued at $941,000 after acquiring an additional 57,943 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Corvus Pharmaceuticals in the third quarter worth $74,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.